Top-Quality Finasteride Powder For Hair Loss CAS:164656-23-9
Finasteride powder represents the foundational active pharmaceutical ingredient (API) behind one of the most rigorously studied pharmacological interventions for androgenetic alopecia. While the general public primarily encounters finasteride in its familiar tablet forms—1 mg Propecia for hair loss or 5 mg Proscar for benign prostatic hyperplasia—the powder itself is the substance from which all these formulations derive. Understanding finasteride powder in its raw form offers unique insights into the compound's true properties, its behavior across different delivery systems, and the factors that influence its clinical performance.
What Is Finasteride Powder?
Finasteride powder is a synthetic 4-azasteroid compound with the chemical formula C₂₃H₃₆N₂O₂ and a molecular weight of 372.55 g/mol. It appears as a white to off-white crystalline powder, practically insoluble in water but readily soluble in organic solvents such as ethanol, methanol, chloroform, and dimethyl sulfoxide (DMSO).
What distinguishes top-quality finasteride powder from inferior grades is purity. Pharmaceutical-grade material typically assays at ≥98% purity when measured by high-performance liquid chromatography (HPLC). This seemingly small percentage difference carries substantial clinical significance-impurities can affect dissolution rates, stability profiles, and ultimately bioavailability. Top-tier powder also demonstrates consistent particle size distribution, which directly influences how the drug dissolves and absorbs when formulated into final products.
Chemically, finasteride acts as a competitive and specific inhibitor of Type II 5α-reductase, the intracellular enzyme responsible for converting the androgen testosterone into the more potent dihydrotestosterone (DHT). The compound binds to the enzyme with approximately 100-fold greater affinity for the Type II isozyme over the Type I isozyme. This selectivity is not accidental-it is the molecular basis for finasteride's therapeutic window, as Type II 5α-reductase predominates in scalp hair follicles and the prostate, whereas Type I is more abundant in skin and sebaceous glands.
Physical and Chemical Properties That Matter
The solubility characteristics of finasteride powder deserve particular attention because they fundamentally shape its pharmacokinetic behavior. The compound is practically insoluble in water-a BCS Class II drug with low solubility but high permeability. This property means that dissolution in the gastrointestinal tract is the rate-limiting step for oral absorption. When formulated as a tablet, the powder must be carefully processed with appropriate excipients to ensure adequate dissolution.
The melting point of finasteride falls within the range of 252–254°C, indicating good thermal stability. Storage conditions significantly impact longevity: lyophilized powder remains stable for up to 36 months when kept desiccated at -20°C, while solutions should be used within three months to prevent potency loss. Short-term storage at room temperature is acceptable, but long-term preservation demands freezing conditions.
Particle size emerges as a surprisingly critical variable. Research has demonstrated that micronized finasteride achieves significantly higher concentrations within target tissues compared to both the pure drug and nano-sized formulations. This finding challenges the assumption that smaller is always better-there exists an optimal particle size range that maximizes tissue penetration without compromising dissolution kinetics.
Applications Beyond the Tablet
While oral tablets remain the dominant delivery vehicle, finasteride powder finds application across an expanding array of formulation strategies. The powder form enables flexibility that finished tablets cannot provide.
Topical Formulations: The systemic side effects associated with oral finasteride-particularly sexual dysfunction and mood alterations-have driven substantial interest in topical delivery. Finasteride powder can be incorporated into solutions, gels, foams, and sprays for direct scalp application. The logic is compelling: deliver the drug directly to the target tissue (hair follicles) while minimizing systemic exposure. However, the compound's lipophilic nature and poor water solubility present formulation challenges that require sophisticated approaches such as self-microemulsifying drug delivery systems (SMEDDS).
Microneedle Delivery: One of the most innovative applications involves powder-carrying microneedles (PCMs)-a patch-less, self-administered powder delivery technique that encapsulates finasteride powder for intradermal administration. This approach overcomes the limitations of conventional delivery systems by enabling enhanced transdermal transport when combined with diffusion enhancers applied at the implantation site.
Compounding and Custom Dosing: For patients requiring non-standard doses or those who cannot tolerate tablet excipients, finasteride powder enables customized compounding. This application requires precision weighing and thorough understanding of the powder's properties to ensure dose accuracy.
Bioavailability Enhancement: The powder's poor aqueous solubility has inspired research into solid SMEDDS formulations. Spray-drying finasteride powder with maltodextrin and leucin carriers has yielded products demonstrating 129.35% relative bioavailability compared with commercial tablets. This represents a substantial improvement-potentially allowing for reduced therapeutic doses with corresponding decreases in side effect profiles and treatment costs.
Clinical Benefits: What the Powder Delivers
When properly formulated and administered, finasteride powder delivers the same clinical benefits as its tablet counterparts-but with potential for optimization through advanced delivery systems.
The primary benefit is DHT suppression. At the standard 1 mg daily dose, finasteride reduces serum DHT by approximately 70%. Scalp DHT concentrations decrease even more dramatically because Type II 5α-reductase predominates in hair follicles. This reduction interrupts the pathogenic process of androgenetic alopecia: DHT binds to androgen receptors in genetically susceptible follicles, triggering miniaturization-the progressive shortening of the anagen (growth) phase and eventual conversion of terminal hairs to vellus-like hairs.
Clinical trial data demonstrate that finasteride 1 mg/day significantly increases total hair count compared with placebo. At 24 weeks, the mean difference reaches 12.4 hairs/cm²; by 48 weeks, this increases to 16.4 hairs/cm². Over a two-year period, finasteride can reduce hair loss by 30–40%. The treatment slows disease progression in the majority of men and produces visible regrowth in approximately two-thirds of users.
Importantly, the efficacy of 1 mg and 5 mg daily doses does not differ significantly for hair loss indications. This finding underscores that the DHT suppression achieved at 1 mg is already near-maximal for scalp effects-higher doses do not yield additional hair benefits but do increase side effect risk.
Dosage, Cycle, and the Question of Duration
The standard dosage for male pattern hair loss is 1 mg administered once daily, taken at the same time each day with or without food. There is no evidence that dose escalation enhances efficacy.
The concept of a "cycle" in the context of finasteride is fundamentally different from that of anabolic steroids or other performance-enhancing substances. Finasteride is not cycled-it is a continuous maintenance therapy. The rationale is straightforward: DHT suppression must be sustained to protect susceptible follicles. Intermittent dosing allows DHT levels to rebound, exposing follicles to renewed androgenic insult.
Clinical response follows a predictable timeline. Three to six months of continuous daily treatment are typically required before evidence of hair loss stabilization becomes apparent. Visible regrowth, when it occurs, usually manifests between six and twelve months. Maximum benefit is often achieved at the two-year mark.
Discontinuation reverses these gains. Within several weeks of stopping finasteride, serum DHT levels gradually return to baseline. Over the subsequent months, the protective effect on hair follicles diminishes, and hair loss resumes at the rate that would have occurred without treatment. This "drug dependency" phenomenon means that finasteride must be viewed as a long-term commitment rather than a short-term intervention.
Half-Life and Pharmacokinetic Profile
The terminal elimination half-life of finasteride averages 6 to 8 hours. In men aged 18–60 years, the mean half-life is approximately 6 hours, while in those over 70, it extends to about 8 hours-a difference of no clinical significance that does not warrant dose adjustment.
Peak plasma concentrations are achieved 1 to 2 hours after oral administration. The drug is approximately 90% bound to plasma proteins. Finasteride undergoes hepatic metabolism to a series of five metabolites, of which two retain activity-though both possess less than 20% of the parent compound's 5α-reductase inhibitory capacity.
Despite its relatively short half-life, finasteride demonstrates slow accumulation with multiple dosing. This paradoxical observation reflects the drug's mechanism: it forms an extremely stable enzyme-bound NADP-dihydrofinasteride adduct that is only slowly processed. The enzyme inhibition persists beyond the drug's presence in circulation, creating a pharmacodynamic effect that outlasts the pharmacokinetic half-life.
The duration of clinical action extends well beyond the elimination half-life. One source notes a duration of approximately two weeks for effects on urinary tract symptoms and hair regrowth. This extended pharmacodynamic effect explains why missing a single dose does not immediately compromise treatment efficacy.
Post-Cycle Therapy: A Misnomer Worth Clarifying
The term "post-cycle therapy" (PCT) originates in the context of anabolic steroid use, where it refers to protocols designed to restore endogenous testosterone production after exogenous androgen suppression. Applying this concept to finasteride requires careful distinction.
For men using finasteride solely for hair loss, there is no conventional PCT. Finasteride does not suppress testosterone production-it inhibits its conversion to DHT. Testosterone levels actually rise modestly (typically 10–15%) as less is converted. Therefore, there is no hypothalamic-pituitary-gonadal axis suppression to reverse.
However, the term acquires meaning in specific contexts. For men who have been using finasteride while concurrently running anabolic steroid cycles, the situation differs. During PCT for fertility restoration or hormonal recovery, finasteride should be stopped for the entire duration of the protocol because the regimen is specifically designed to restore fertility and endogenous testosterone production. In this limited window, recovery of fertility and hormonal balance takes precedence over the cosmetic benefits of finasteride.
For the typical hair loss patient discontinuing finasteride, the primary consideration is not PCT but rather the expectation of hair loss resumption. A realistic post-discontinuation plan might include transitioning to other hair preservation strategies such as topical minoxidil, low-level laser therapy, or ketoconazole shampoo. Some clinicians recommend tapering rather than abrupt cessation, though evidence supporting this practice is limited.
The phenomenon of post-finasteride syndrome (PFS)-persistent sexual, neurological, and psychological side effects that continue after drug discontinuation-represents a distinct and serious consideration. This condition, while rare, has been documented in men who used finasteride for hair loss and experienced adverse effects that did not resolve upon cessation. PFS is not a PCT issue but rather a potential complication that underscores the importance of informed consent and careful risk-benefit assessment before initiating treatment.
Quality Considerations and Sourcing
The designation "top-quality" finasteride powder encompasses multiple dimensions beyond simple purity. Pharmaceutical-grade material must meet strict specifications for residual solvents, heavy metals, microbial limits, and related substances. The powder should demonstrate consistent dissolution profiles and stability under recommended storage conditions.
For research and compounding purposes, sourcing from reputable suppliers with documented quality control procedures is essential. Certificates of analysis should verify HPLC purity, provide particle size data, and specify storage recommendations. The powder should be stored desiccated at controlled temperatures, with protection from light and oxidizing agents.
Clinical Data
|
Trade names |
Proscar, Propecia, Finide,MK-906; YM-152; L-652,931; 17β-(N-tert-Butylcarbamoyl)-4-aza-5α-androst-1-en-3-one; N-(1,1-Dimethylethyl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide |
|
CAS |
98319-26-7 |
|
Molar mass |
372.553 |
|
MF |
C23H36N2O2 |
|
Purity |
Above 98% |
|
Apprarance |
White Crystalline Powder |
Any needs, please contact us
Email: Jasonraws106@gmail.com
WhatsApp: +86-15572565525
Telegram: +86-15871669785
Conclusion: The Powder's Place in Hair Restoration
Finasteride powder, in its pure form, represents the active chemical entity that has transformed the management of androgenetic alopecia. Its selective inhibition of Type II 5α-reductase, favorable pharmacokinetic profile, and demonstrated efficacy in clinical trials have established it as a cornerstone of medical hair restoration.
The powder form enables formulation flexibility that finished tablets cannot provide-from topical solutions to microneedle delivery systems to bioavailability-enhanced formulations. Understanding the physical and chemical properties of the powder is essential for optimizing these delivery strategies.
For the end user, the clinical considerations remain consistent regardless of the form: 1 mg daily, continuous administration, realistic expectations about the timeline of response, and awareness that benefits depend on sustained treatment. The half-life of 6–8 hours belies a pharmacodynamic effect that extends well beyond drug presence, while the absence of conventional PCT requirements reflects finasteride's mechanism of DHT inhibition rather than testosterone suppression.
Top-quality finasteride powder, properly formulated and responsibly used, offers a scientifically validated approach to preserving hair in genetically predisposed individuals. Its value lies not in novelty or complexity but in the elegance of its mechanism and the consistency of its clinical outcomes-attributes that have sustained its position as a first-line therapy for over three decades.
Hot Tags: top-quality finasteride powder for hair loss cas:164656-23-9, China top-quality finasteride powder for hair loss cas:164656-23-9 manufacturers, suppliers, factory, Anabolic androgenic steroid Trenbolone Acetate, Anabolic Sterol Esters Clostebol Acetate, Testosterone Enanthate, Testosterone Phenylpropionate, Trenbolone Hexahydrobenzyl Cabonate, Vardenafil
